Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Parambeth, Joseph Cyrus![]() |
|
dc.contributor.author | Fosgate, Geoffrey Theodore![]() |
|
dc.contributor.author | Suchodolski, Jan S.![]() |
|
dc.contributor.author | Lidbury, Jonathan A.![]() |
|
dc.contributor.author | Steiner, Jorg M.![]() |
|
dc.date.accessioned | 2019-03-05T14:10:20Z | |
dc.date.available | 2019-03-05T14:10:20Z | |
dc.date.issued | 2018-09 | |
dc.description.abstract | BACKGROUND : Pancreatic enzyme supplements for the treatment of exocrine pancreatic insufficiency (EPI) in dogs can be uncoated or enteric coated. Enteric coated supplements might be advantageous. HYPOTHESIS/OBJECTIVES : Enteric coated enzyme supplements are superior to uncoated supplements in dogs with clinical EPI. ANIMALS : Eleven dogs with naturally occurring EPI that were apparently free from other diseases. METHODS : Randomized, blinded, controlled cross-over clinical trial comparing a novel microencapsulated enteric coated enzyme supplement to a commercially available uncoated product in dogs with clinical EPI. Search of serum canine serum trypsin-like immunoreactivity concentration ≤ 2.5 μg/L in the Gastrointestinal Laboratory database was used to identify dogs with EPI. RESULTS : There was no difference −4.46% (95% CI: −7.97%-–0.96%; P = .15) in the % acid hydrolysis fecal fat (primary outcome) between the enteric coated formulation (median: 11.8%; range 6.4%-17.0%) and the uncoated pancreatic enzyme replacement product (median: 17.5%; range: 5.2%-24.9%) in the 11 dogs that completed the study. Other variables did not differ between treatments. CONCLUSIONS AND CLINICAL IMPORTANCE : This study, which had low statistical power, did not detect a difference between formulations. | en_ZA |
dc.description.department | Production Animal Studies | en_ZA |
dc.description.librarian | am2019 | en_ZA |
dc.description.sponsorship | Eurovet Animal Health BV, Grant/Award Number: 11.001 | en_ZA |
dc.description.uri | http://wileyonlinelibrary.com/journal/jvim | en_ZA |
dc.identifier.citation | Parambeth, J.C., Fosgate, G.T., Suchodolski, J.S. et al. 2018, 'Randomized placebo controlled clinical trial of an enteric coated micro-pelleted formulation of a pancreatic enzyme supplement in dogs with exocrine pancreatic insufficiency', Journal of Veterinary Internal Medicine, vol. 32, no. 5, pp. 1591-1599. | en_ZA |
dc.identifier.issn | 0891-6640 (print) | |
dc.identifier.issn | 1939-1676 (online) | |
dc.identifier.other | 10.1111/jvim.15235 | |
dc.identifier.uri | http://hdl.handle.net/2263/68574 | |
dc.language.iso | en | en_ZA |
dc.publisher | Wiley | en_ZA |
dc.rights | © 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License. | en_ZA |
dc.subject | Enteric coating | en_ZA |
dc.subject | Randomized clinical trial | en_ZA |
dc.subject | Exocrine pancreatic insufficiency (EPI) | en_ZA |
dc.subject | Dogs | en_ZA |
dc.subject | Pancreatic enzyme supplements | en_ZA |
dc.title | Randomized placebo controlled clinical trial of an enteric coated micro-pelleted formulation of a pancreatic enzyme supplement in dogs with exocrine pancreatic insufficiency | en_ZA |
dc.type | Article | en_ZA |